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ABSTRACT
Apurinic/apyrimidinic endonuclease-1 (APE1) is a
multifunctional DNA repair/gene regulatory pro-
tein in mammalian cells, and was recently reported
to be phosphorylated at Thr233 by CDK5. We here
report that ubiquitination of T233E APE1, a mim-
icry of phospho-T233 APE1, was markedly incre-
ased in multiple cell lines. Expression of CDK5
enhanced monoubiquitination of endogenous APE1.
Polyubiquitinated APE1 was decreased when K48R
ubiquitin was expressed, suggesting that poly-
ubiquitination was mediated mainly through Lys48
of ubiquitin. The ubiquitination activity of MDM2,
consistent in its role for APE1 ubiquitination, was
increased for T233E APE1 compared to the wild-
type APE1. In mouse embryonic fibroblasts lacking
the MDM2 gene, ubiquitination of T233E APE1 was
still observed probably because of the decreased
degradation activity for monoubiquitinated APE1
and because of backup E3 ligases in the cells.
Monoubiquitinated APE1 was present in the nucleus,
and analyzing global gene expression profiles with
or without induction of a ubiquitin-APE1 fusion gene
suggested that monoubiquitination enhanced the
gene suppression activity of APE1. These data reveal
a delicate balance of ubiquitination and phosphoryl-
ation activities that alter the gene regulatory
function of APE1.
INTRODUCTION
Oxidative stress and alkylating reagents spontaneously
generate DNA damage that is mainly repaired by DNA
base excision repair (BER) (1). Apurinic/apyrimidinic
(AP) endonucleases (APEs) play an essential role in
BER. Without APE activity, such damage is sufﬁcient to
stall DNA replication and to cause cell death (2–5). In
mammals, Apurinic/apyrimidinic endonuclease-1 (APE1)
is responsible for the APE activity (6–8). Depletion of
APE1 in mouse and cultured cells leads to embryonic
lethality and apoptotic cell death, respectively (4,5).
APE1 has at least two types of gene regulatory func-
tions that appear unrelated to its DNA repair functions
(9). Known as the redox factor 1 (Ref-1), APE1 activates
AP-1, NFkB and other transcription factors important in
cancer biology by mediating intracellular redox signaling
(10–13). In addition, APE1 acts as a transcriptional co-
repressor by binding DNA cis-elements called nCaREs
(negative calcium response elements), which are found in
upstreams of genes related to calcium dependent-
homeostasis (14–17). Histone acetyltransferase (HAT)
p300 acetylates APE1 at two N-terminal Lys residues
(K6/7) and increases APE1’s DNA binding activity (18).
Interaction of APE1 with HDAC1 likely enhances the
suppression of genes involved in the nCaRE dependent
regulation (18). More recently the other Lys residues
(K27, 31, 32, 35) in the N-terminal 6-kDa region of
which function has not been understood clearly, were
found to be acetylated (19).
In addition to acetylation and S-nitrosation (20), two
other PTMs on APE1 were recently reported, i.e.
ubiquitination (21,22) and phosphorylation (23). APE1
was ubiquitinated, which was enhanced by transient
up-regulation of MDM2. Ubiquitin-induced APE1 deg-
radation may sensitize cells to apoptosis. While APE1
gene downregulation is followed by apoptotic cell death
(4,5,24,25), a higher expression of APE1 is linked
to chemo/radiation-resistant cancer cells (26–29). As re-
searchers attempt to improve the outcomes of non-
invasive treatments for tumors (30,31), the mechanism
involved in APE1 ubiquitination is an important subject
to understand.
APE1 phosphorylation was reported earlier (32–34),
but the matter was refreshed by Huang et al. (23) who
found that APE1 was phosphorylated in vivo speciﬁcally
at Thr-233 by CDK5. CDK5 is a paralog of cell cycle-
dependent kinases CDK2 and CDK4/6, and its activity
is high in post-mitotic neuronal cells (35–37). It has been
suggested by numerous studies that CDK5 is critical for
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intriguing that phosphorylated APE1 and its mimicry
T233E APE1 showed decreased APE activity, and that
the phosphorylated APE1 was more abundantly found
in cells from brains of Parkinson’s and Alzheimer’s
patients (23).
We are interested in the fact that in some conditions
APE1 was down-modulated (23). Such immediate
downregulation is indicative of protein degradation de-
pendent on ubiquitination. In this report, we show that
phosphorylation at T233 of APE1 markedly increased its
ubiquitination and that the degradation was regulated by
MDM2. A mechanism that links T233 phosphorylation to
APE1 ubiquitination is discussed.
MATERIALS AND METHODS
Cell lines
A colon carcinoma cell line HCT116 (38) was grown as
described previously (22). A549, a human lung adenocar-
cinoma cell line was purchased from ATCC. JHU28 and
JHU13, human oral squamous carcinoma cell lines, were
provided by Dr R. Walvekar (LSUHSC) and Dr R. Ferris
(University of Pittsburgh). 2DN cells (p53
 /  MDM2
 / )
mouse embryonic ﬁbroblasts (MEFs) were originally de-
veloped in Dr Lozano’s lab and kindly provided by Dr
Iwakuma (39). HCT116 and A549 carry the wild-type (wt)
p53 gene, and we also conﬁrmed that JHU28 carry the
wt p53 gene (data not shown). Stable transfectants of
HCT116 that harbor either control vector (pSIREN-
RetroQ) or shAPE1 vector (generous gift from
Dr Crowe) were established as previously described (40).
The 293 T-Rex Flp cell line (Invitrogen) was cultured in
DMEM/F12 medium with 10% FBS, 100mg/ml zeocin
and 15mg/ml blasticidin. Stable 293 transfectants for
pOG44 (Flp recombinase) and the tet-on expression vec-
tors (derivatives of pcDNA5/FRT/TO, Invitrogen and
Supplementary Figure S2) were selected with 100mg/ml
hygromycin B after transfection. All cells were cultured in
the same condition as for HCT116. DNA Transfection
was carried out using lipofectamine2000 (Invitrogen)
following the vendor’s instruction.
DNA and chemicals
The wtAPE1 cDNA was cloned by RT–PCR using total
RNA from JHU13. The clone carries identical coding
sequence to that in NCBI (GeneID 328) and is regarded
as wt in this study. The human CDK5 and p35 genes were
obtained from Addgene. Other genes were cloned by PCR
using human quick-clone cDNA (Clontech), and con-
ﬁrmed to carry the wt sequences (ACGT, Chicago).
Chemicals were purchased from Sigma unless otherwise
noted.
Immunoblot assay (western blot)
A standard protocol was used for all immunoblot assays
using PVDF membrane (Bio-Rad). Antibodies were
purchased from Santa Cruz, including a secondary
antibody (sc-2031) and primary antibodies for APE1
(sc-55498), CDK5 (sc-6247), p35 (sc-5614) and b-tubulin
(sc-58884).
Ubiquitination assay, co-immunoprecipitation (Co-IP) and
fractionation of nuclei and cytosol
The ubiquitination assay was carried out as described pre-
viously (22). Co-IP was also carried out as the previous
study using Fk-2 (Enzo) and M2-FLAG antibody
(Sigma). For separating nuclear and cytosolic fractions,
cells expressing T233E APE1 was washed with PBS
twice, then extracted with nuclear/cytosol protein frac-
tionation kit (BioVision) with the vendor’s protocol.
HSP90 and Lap2 antibodies are from SCBT.
Immunocytochemistry of T233E APE1
2DN cells transiently expressing T233E APE1 from
IRES-hrGFP1a (Stratagene) were ﬁxed in 3.7% formalde-
hyde, permeabilized with 0.2% TritonX100, and washed
with PBS. After blocking in PBS containing 1% bovine
serum albumin (PBS/BSA), the ﬁxed cells were incubated
with an APE1 antibody (rabbit polyclonal, raised with
full-length hAPE1) for 2h, and with an anti-rabbit IgG
conjugated to rhodamine (Chemicon) for 1h. Cells were
stained with DAPI and mounted on glass plates, and
analyzed with Nikon TE2000 epiﬂuorescence microscope.
Total RNA extraction and gene expression array proﬁling
Three HEK293 derivatives expressing either none (vector),
wtAPE1, or Ub-APE1 fusion linked at APE1’s 24th Lys,
were incubated with/without doxycycline (dox) 2mg/ml
for 16h. Each  /+ dox cultures were triplicated. Total
RNA from were extracted (Qiagen), and then analyzed by
LSU’s bioinformatics core. The quality and quantity of total
RNA were assessed using ND-1000 Spectrophometer
(NanoDrop, Wilmington, DE), NanoChip assay and
Bioanalyzer 2100 (Agilent). All samples were of high in-
tegrity with RIN # >7seven and A260/280 >1.8.
Procedures for cDNA synthesis, sense target labeling
and hybridization were carried out as described at
http://media.affymetrix.com/support/technical/appnotes/
wt_appnote.pdf (Affymetrix, Redwood City, CA, USA).
All experiments were performed using GeneChip Exon 1.0
ST Arrays and Whole Transcript Sense Target labeling
Assay (version 4, Affymetrix). Overnight hybridization
of fragmented single-stranded DNA was carried out in
an Affymetrix GeneChip Hybridization Oven 640, then
washed and stained with streptavidin-phycoerythrin
using GeneChip 450 Microﬂuidics Station (Affymetrix).
Chips were scanned with an Affymetrix High Resolution
3000 (G7) scanner. Signal and background intensities were
quantitated by pixel intensity using Affymetrix GeneChip
Operating Software (GCOS 1.4). Array quality control
assessment was carried out using Robust Multi-chip
Analysis (RMA) workﬂow for Core probesets in
Expression Console (Affymetrix). Gene-level analysis for
differential gene expression was analyzed in GeneSpring
7.3  (Agilent Technologies) using the sample CHP ﬁles.
The RMA method was used for the background correc-
tion, normalization and average expression measures for
the probesets. An expression ﬁlter (20 percentile cutoff)
8018 Nucleic Acids Research, 2011,Vol.39, No. 18was applied to remove genes with low signal intensity
values. For differential gene expression analysis, the
Welch ANOVA test with asymptotic P-value computation
was applied and transcripts with P-value (<0.05) and fold
change (2.0-fold) were selected.
RESULTS
T233E APE1, in which Glu was substituted for Thr at
233th amino acid residue, was recently used to mimic
phosphorylated APE1 by CDK5 (23). To test whether
phosphorylation of T233 affects APE1 ubiquitination, a
plasmid vector encoding human T233E APE1 was transi-
ently expressed in HCT116 sh-ctl, a human colon car-
cinoma cell lines stably carrying am empty sh-vector
(lanes 1–4, Figure 1A). To observe the high molecular
weight-bands (HWBs) that were speciﬁcally detected
with anti-APE1 antibodies, signals of HWBs were separ-
ately detected from that of the intact APE1 protein.
The amount of HWBs was increased in the cells wit
T233E (Figure 1A, lane 3) compared to the wt-APE1
(lane 1). The position of one of HWBs (ﬁlled arrow)
migrated slightly below b-tubulin (49.7kDa), above
b-actin (41kDa), approximately matching to the calcul-
ated molecular weight (44kDa) of monoubiquitinated
APE1 (muAPE1), although the exact migrating pos-
ition may be different due to the branched structure of
ubiquitin conjugation. Moreover, the band position
matched to that of recombinant muAPE1 prepared from
Escherichia coli (Supplementary Figure S1A). A band
(Figure 1A, open arrow) smaller than the recombinant
muAPE1 was likely due to a subsequent truncation of
ubiquitinated APE1 (uAPE1). Although it is not clear
whether ubiquitination induced the cleavage reaction, it
has been known that N-terminal sites are susceptible
to spontaneous hydrolytic cleavage. In any case, the
band corresponding to monoubiquitinated APE1 was
the major product among HWBs. Treatment of the
Figure 1. Enhanced ubiquitination of T233E APE1. (A) HCT116 ctl (1–4), HCT116 expressing shAPE1 (5–8) and SW480 (9–12) transfected with the
wtAPE1 (1, 2, 5, 6, 9, 10), T233E APE1 (3, 4, 7, 8, 11, 12). After 24h, cells of even lanes were treated with MG132 for 3h, and cell extracts were
analyzed with immunoblotting (IB) with a monoclonal APE1 antibody (aAPE1). Intact APE1 (iAPE1) was blotted separately from uAPE1.
Reblotted b-tubulin (50kD) and b-actin (41kD) were used as size markers. (B) A549 transfected with vector ctl (1, 6), wtAPE1 (3), or T233E
(2, 4, 5, 7) with 3h MG132 treatment (5). Lanes 6 and 7, unlike 1–5, intact and uAPE1 were blotted together to determine the relative amount of
uAPE1 compared with the intact APE1. (C and D) His-Ub assay. A549 transfected with the T233E APE1 and indicated ubiquitin (Ub) genes. Total
and enriched ubAPE1 by nickel afﬁnity beads (eluted) were detected with aAPE1. Top, uAPE1 and intact APE1 in total fractions; bottom, uAPE1 in
eluted fraction. Arrows indicate positions of muAPE1 (closed), puAPE1 (double closed), and truncated muAPE1 (open).
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teasome, increased HWB formation to a much greater ex-
tent (Figure 1A, compare lanes 3 and 4), along with the
di-ubiquitinated APE1 (double ﬁlled arrow, Figure 1A).
Although the monoclonal antibody used in this study was
highly speciﬁc to APE1, to further conﬁrm that the HWB
formation was speciﬁc to APE1 and not due to some
cross-reactivity of the antibody, we transiently expressed
the wt and T233E APE1 in HCT116 derivative that
expresses APE1 shRNA (HCT116 shAPE1, lanes 5–8,
Figure 1A). This cell line shows an extremely low expres-
sion of the intact APE1 protein ( 3% of the parental cell
line). The cells also effectively suppressed the transiently
expressed APE1 with the very low amount of unmodiﬁed
intact APE1 (lanes 5–8 versus 1–4). The HWBs diminished
in this cell line, which conﬁrmed that the HWBs were
speciﬁc to APE1. These observations suggested that the
T233E alteration increased muAPE1 and puAPE1
(polyubiquitinated APE1), and that puAPE1 is susceptible
to the 26S degradation pathway.
Essentially identical results were obtained with SW480,
another colon carcinoma cell line (Figure 1A), and
JHU28, an oral squamous carcinoma cell line (data not
shown) (41). A549, a human lung carcinoma cell line,
showed a substantial difference in its accumulation of
HWB (Figure 1B). HWB in A549 was readily visible with-
out MG132 which only had a minimum effect (lanes 4
and 5), suggesting that A549 was particularly tolerant of
degradation of puAPE1 and increased the stable existence
of muAPE1. In A549, the relative amount of uAPE1
(lane 7) over the total amount of APE1 (intact APE1
and uAPE1 combined) was calculated to be 20.2±
12.1% based on three independent experiments where im-
munoblot signals were not saturated. These results with
multiple cell lines suggest that T233E enhancement for
uAPE1 formation is a general phenomenon and that the
consequence of the uAPE1 protein may differ from one
cell type to another. It should be noted that cell lines tested
above carry the wild-type p53 gene except for SW480 (42),
suggesting that the variability of ubiquitination activity on
APE1 was not due to the genetic status of the p53 gene.
To conﬁrm that HWB formation was due to APE1
ubiquitination, a ubiquitination assay was carried out
using the ubiquitin gene tagged with a histidine hexamer
(His-Ub) (22). In Figure 1C, T233E APE1 was co-
expressed in A549 with three kinds of His-Ub genes,
namely, the wild-type Ub, G76A Ub, and K48R G76A
Ub. The C-terminal Ala substitution (G76A) in ubiquitin
increases resistance to intracellular deubiquitination act-
ivities (22), whereas the K48R Ub lacks the critical Lys
residue necessary for polyubiquitination (43,44). When
T233E APE1 was co-expressed with ubiquitin, the
amount of intact APE1 and uAPE1 in the total fractions
were noticeably decreased (lane 3 compared to 2), suggest-
ing that over-expression of ubiquitin facilitated degrad-
ation of uAPE1 (see below). In the eluted fractions,
HWB speciﬁc to APE1 appeared depending on the
His-Ub expression (lanes 3–5). The amount of HWBs
(uAPE1) was much higher with the G76A ubiquitin
(lane 5) than with the K48R G76A ubiquitin (lane 4),
suggesting that puAPE1 was mainly formed via K48.
In addition, the amount of uAPE1 by G76A was larger
than that of the wt-ubiquitin, suggesting that the presence
of an intracellular deubiquitinase activity of which
reaction was blocked by the G76A missense.
To examine the nature of the uAPE1 in detail, two add-
itional His-Ub genes were constructed in the background
of G76A. The ‘Ub
allR’ has Arg substitutions for all of
its seven Lys, and ‘Ub
allRbutK48’ has Arg substitutions
in all but 48th Lys residue. We compared ubiquitination of
T233E APE1 with the three ubiquitin subforms (Figure 1D).
Ub and Ub
allRbutK48 were both enhanced APE1 ubiquiti-
nation (Figure 1D, lanes 2 and 3). However, a larger
amount of HWBs (puAPE1) was puriﬁed with the G76A
Ub than with Ub
allRbutK48, possibly implying that K48
was not the sole ubiquitin-acceptor for puAPE1 formation
(Figure 1D, lane 3). Amount of puAPE1 with Ub
allR was
substantially decreased in the total fraction (lane 4, top),
and was negligible in the eluted fraction, compared to the
prominent existence of muAPE1 (lane 4, bottom). These
results supported our conclusion that the HWB was
formed by ubiquitination. Our attempt to detect APE1
conjugation to small ubiquitin like-modiﬁers, i.e.
SUMO, Nedd8 and ISG15, was previously unsuccessful
(22). We examined the possibility that the T233 modiﬁca-
tion might enhance such modiﬁer conjugations as well.
Unlike ubiquitin, however, none of the above small mol-
ecule modiﬁers revealed HWBs on T233E APE1 (data not
shown). Taken together, we concluded that ubiquitin was
the unique small molecule modiﬁer even for T233E APE1.
We previously reported the role of MDM2 as an E3
ligase for APE1 ubiquitination (22). Here, T233E APE1
was expressed in 2DN cells, mouse embryonic ﬁbroblasts
(MEFs) generated from p53
 /  MDM2
 /  mice (39). The
2DN cells expressing T233E APE1 showed increased
uAPE1 (Figure 2A, lanes 3 versus 2), indicating that
there were other E3 ligase(s) that could complement
MDM2 for ubiquitination of APE1. We tested the effect
of over-expression of MDM2 and ubiquitin genes in the
MDM2
 /  cells on the amount of uAPE1 generation. The
MDM2 gene was co-expressed in the 2DN cells along with
T233E APE1 (Figure 2B, lane 2). In this condition, the
expression of MDM2 caused a decrease of uAPE1. We
also co-expressed the ubiquitin and T233E APE1 in
the cells, which also resulted in a reduction of uAPE1
(Figure 2B, lane 5 and also Figure 1C). The amount of
uAPE1 in these conditions increased after treating the cells
with MG132 (Supplementary Figure S5A), suggesting that
expressing either MDM2 or ubiquitin could enhance the
degradation process. To ascertain the role of MDM2 in
the ubiquitination reaction, an APE1 ubiquitination en-
vironment was generated in E. coli (Figure 2C). Five
human genes necessary for APE1 ubiquitination were sim-
ultaneously expressed in E. coli, i.e. ubiquitin ligases E1
(uba1), E2 (UbcH5b), E3 (MDM2), His-tagged ubiquitin,
and APE1 (22,45). While the wtAPE1 led to puAPE1 ac-
cumulation at 37 C, the T233E substitution enhanced
puAPE1 formation (lane 5 versus 3). The result indicated
that MDM2 was capable of ubiquitinating APE1, a
reaction that was enhanced with the T233E substitution
in APE1. Together with the in vitro reactions previously
reported (22) and the increasing interaction between
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we concluded that MDM2 was a functional E3 ligase for
APE1, but there were backup E3 ligases in the cells.
To obtain evidence of enhancement of ubiquitination
for endogenous APE1, the CDK5 and its activator p35
genes were co-expressed in the 2DN cells, and ubiquitin-
conjugated proteins were immunoprecipitated by a mono-
clonal antibody speciﬁc to Ub-conjugates (46). The
immunoprecipitated fractions were then analyzed for
uAPE1 (Figure 3). The muAPE1 speciﬁc bands were de-
tected only when the CDK5/p35 and ub were expressed in
the cells (lane 4). In addition, ubiquitinated APE1
catalyzed by MDM2 was inhibited by treating the cells
with roscovitine, a potent inhibitor of the phosphorylation
reaction of CDK5 (Supplementary Figure S5B). With
these results, we concluded that ubiquitination of en-
dogenous APE1 was triggered with T233 phosphorylation
by CDK5/p35. It should be noted that puAPE1 was not
detected in the IP fractions, presumably because puAPE1
was sensitive to degradation and was less stable than
muAPE1. This inference is consistent with our recombin-
ant muAPE1 puriﬁcation, where puAPE1 could not be
puriﬁed (Supplementary Figure S1A), even though
puAPE1 was accumulated (Figure 2C).
Lys residues 24, 25 and 27 in APE were identiﬁed as
ubiquitin acceptor sites (22). The K24/25/27R triple Arg
substitution mutant was created in the T233E back-
ground, and tested if the protein was ubiquitinated
(Figure 4A). To calculate the ubiquitination efﬁciency,
we used an internal control to normalize the transfection
efﬁciency: T233E APE1 in which all Lys residues were
converted to Arg (KallR, Supplementary Figure S4), as
ubiquitination on this Lys-less APE1 should be negligible
if any. The amount of uAPE1 was decreased in the K24/
25/27R (Figure 4B,  60% of APE1 with intact Lys).
ND41 APE1 (41 amino acid truncation from the
N-terminus) in the T233E background resulted in further
decrease in ubiquitination (Figure 4B, 9%). We thus
Figure 2. Dependency of HWB appearance on ubiquitin and MDM2. (A) 2DN (p53
 /  MDM2
 / ) transfected with control vector (1), the WT
APE1 (2), or the T233E APE1 cDNA (3), and probed with aAPE1 for uAPE1 (top) and intact APE1 (iAPE1, bot). (B) 2DN expressing T233E alone
(1) or T233E+MDM2 (2), ctl vector (3), T233E (4) and T233E+ubiquitin (5). Top: uAPE1; bottom: intact APE1. (C) APE1 ubiquitination assay in
E. coli BLR(DE3) with Uba1, UbcH5b, MDM2, ubiquitin (2–5) plus wt APE1 (2 and 3) or T233E APE1 (4 and 5) extracted (2 and 4) and incubated
at 37 C for 40min (3 and 5), and analyzed with aAPE1. (1), puriﬁed recombinant muAPE1. Top: uAPE1; rest: intact APE1 and ubiquitination
factors in lanes 2–5 detected in separate immunoblot membranes.
Nucleic Acids Research, 2011,Vol.39, No. 18 8021concluded that K24, 25, 27 are ubiquitin acceptor sites for
T233E APE1, albeit other Lys residues in the N-terminus
may be also involved.
To analyze the subcellular localization of uAPE1,
T233E APE1 was expressed in the 2DN cells along with
hrGFP using a single IRES containing-vector (Figure 5A).
T233E APE1 was found in nuclei exclusively with or
without MG132, indicating that ubiquitination of T233E
APE1 occurred and remained in the nuclei. To support
this observation, HCT116, SW480 and A549 expressing
T233E APE1 was extracted after MG132 treatment
(Figure 5B). A band of size speciﬁc to muAPE1
appeared only with MG132 in the nuclear but not in the
cytosol fraction (Figure 5B, lanes 4 versus 2, 8 versus 6, 12
versus 10). These results were in line with the immuno-
cytochemistry above, that uAPE1 was localized in the
nuclei. We examined if the muAPE1 in nuclei existed
in chromatin assembly by separating the muAPE1 into
total and soluble fractions after formaldehyde cross-
linking treatment, a procedure commonly carried out
during chromatin immunoprecipitation (ChIP) assay
(Figure 5C). In this experiment, majority of muAPE1
turned to be insoluble in the nuclear fractions, indicating
that the modiﬁed APE1 was precipitated along with
genomic DNA and chromatin complexes, while the
intact APE1 was mostly soluble.
We developed stable HEK293 T-Rex cell lines that
express the intact APE1 or muAPE1 fusion proteins in
nuclei (Supplementary Figure S2) with the addition of
doxycycline. With the 293 derivatives, solubility of
muAPE1 in cells was examined (Figure 5D). After expres-
sion of either protein, cells were cross-linked to genomic
DNA by formaldehyde (18). After cell lysis by sonic-
ation, a large fraction of muAPE1 was found insoluble
(Figure 5C, lane 2, top versus bottom). The protein
became soluble after multiple cycles of sonication to
shear the genomic DNA (Figure 5C lane 2) or by a high
salt (0.5M) concentration (lane 3). In contrast, wtAPE1
was soluble in all tested conditions. It should be noted that
recombinant muAPE1 from E. coli was very stable and
soluble (Supplementary Figure S3), and thus it is
unlikely that the muAPE1 in the cells was intrinsically
unstable.
APE1 interacts with histone deacetylase 1 (HDAC1) for
its gene suppressor function (18). The interaction of
HDAC1 with the intact APE1 and mu-APE1 fusion
proteins was examined (Figure 5E). The immunopre-
cipitated fraction contained more muAPE1 proteins than
the intact APE1, suggesting that HDAC1–APE1 inter-
action was enhanced by ubiquitination of APE1, and
possibly contributed to the gene regulatory functions of
APE1.
We determined gene expression proﬁles of the 293 stable
transfectants, i.e. 293/ctl, 293/wtAPE1 and 293/ muAPE1,
with or without 1mg/ml dox. Three sets of independent
RNA preparations (18) were examined in an Affymetrix
GeneChip Exon 1.0 ST Arrays (see Experimental
Procedure for details), and pooled about 15500 genes
that showed statistically meaningful results between
dox±conditions (see ‘Materials and Methods’ section).
Figure 3. Ubiquitination of endogenous APE1 enhanced by CDK5/p35. 2DN cells transfected with vector ctl (1), HA-tagged CDK5 and p35 (2),
G76A ub (3), and HA-CDK5/p35+G76A ub (4), and incubated with MG132. Extracts were immunoprecipitated with Fk2 antibody and analyzed
with aAPE1 and monitored for expression of HA-CDK5 and p35 using antibody speciﬁc to CDK5 and p35.
8022 Nucleic Acids Research, 2011,Vol.39, No. 18Investigating an effect of ubiquitination on APE1’s gene
regulatory function may be complex, because APE1
affects expression of a number of genes in both activation
(via its Ref-1 function) and suppression by very different
mechanisms (mediated via Ref-1 function or via nCaRE
and acetylation, respectively). To answer this question,
we examined the gene expression proﬁles in detail.
Histograms revealing the number of down or upregulated
genes due to dox addition (Supplementary Figure S6A)
indicated that the increased expression of the wtAPE1
gene resulted in more transcriptional downregulation than
activation. This tendency was further enhanced when ub-
APE1 protein was induced, as the skewness became more
negative with a lower kurtosis value (Supplementary
Figure S6). In contrast, the control cell line generated
a near perfect bell-shape histogram (Supplementary
Figure S6) with its skewness near 0 and a much higher
kurtosis value than those of the wtAPE1- or ubAPE1-
expressing cell lines, indicating that the vector alone did
not affect the global gene expression relative to the cases
of wtAPE1 and ub-APE1 expression.
To further elucidate the enhancement of multi-gene sup-
pression by ub-APE1 over intact APE1, we sought for a
similar approach to the work by Enard et al. (47). A
‘distance’ value D was deﬁned (Figure 6) to assess whether
APE1’s activator or repressor function was enhanced by
ubiquitination (Figure 6). With the genes that were
activated by dox (left, Figure 6B), the distributions of
D-values for genes activated by muAPE1 was nearly per-
fectly bell-shaped with the peak at 0 (where d1=d2),
while a slight right shift was observed with wtAPE1
(median=1.32, Figure 6C). A right-shift was present with
genes suppressed by muAPE1 (circles in right panel,
Figure 6B) with median value 2.4 (Figure 6C).
Therefore, the results indicated that ubiquitination
enhanced the gene suppression activity of APE1 more
effectively than the activation.
DISCUSSION
The T233E amino acid substitution, recently analyzed
by Huang et al. (23) was used as a mimicry of T233-
phosphorylated APE1 by CDK5. Considering the
dramatic change and its effect on APE1 conformation,
intracellular levels of APE1 ubiquitination activity might
be affected as well. This prediction was correct, as we
observed the accumulation of uAPE1 from cells express-
ing the T233E APE1. Among tested cell lines, A549 and
MDM2
 /  MEFs were particularly high in generating
uAPE1. While understanding the reason behind the
variable APE1 ubiquitination in the cells is beyond the
goal of this study, these two cells lines helped us elucidate
the mechanism of APE1 ubiquitination.
The puAPE1 formation was mediated by ubiquitin con-
jugation mainly via K48 (Figure 1). Interestingly, puriﬁed
puAPE1 with Ub
KallRbutK48 was less than that with the
wt-Ub, which may be interpreted that some of polyubi-
quitin chain on APE1 is mediated via Lys other than K48.
More technical consideration is necessary to demonstrate
puAPE1 formation via Lys residues other than K48 of
Ub. In any case, our conclusion is that HWB formation
is thoroughly mediated by ubiquitination, as the Ub
KallR
construct failed to form puAPE1 (Figure 1D). Other small
ubiquitin-like modiﬁers also failed to conjugate T233E
APE1.
Eliminating K24/25/27 in APE1 by substituting with
Arg decreased the level of both mono- and poly-
ubiquitination of T233E APE1. Therefore, while the
results indicated the importance of the Lys residues, the
data also imply that ubiquitination may take place at Lys
other than K24/25/27. This was unexpected, considering
that in the previous study ubiquitination on the K24/25/
27R mutant was substantially decreased albeit not com-
pletely (22). It is possible that modiﬁcation of T233 alters
the local conformation and invokes additional Lys accept-
ors to be readily accessible by E3 ligases including
MDM2. The dependency on K24/25/27 for APE1
ubiquitination may also vary with cell types and growth
conditions. Consistent with the previous study (22),
deleting the N-terminal 41 amino acid residues decreased
the ubiquitination activity further, strongly indicating that
APE1 ubiquitination was controlled by the N-terminus.
Interestingly, Fantini et al recently reported that the
Figure 4. Ubiquitin acceptor Lys in APE1. (A) A549 was transiently
transfected with cDNA encoding ‘KallR’ (all Lys residues in APE1
were altered to Arg) as an internal control for transfection
(Supplementary Figure S4), along with wtAPE1 (1), T233E (2),
T233E K24/25/27R (3) and T233E ND41 APE1 (N-terminal deletion
of 41 amino acid residues). (Top) Ubiquitinated APE1; Bot) intact
APE1, KallR and ND41 are shown. KallR mutant APE1 migrates
slightly faster than the intact APE1 in SDS/PAGE, due to the differ-
ence in amino-acid composition from the wtAPE1 (Supplementary
Figure S4). (B) Relative intensities of ubiquitinated APE1 were
calculated from three independent experiments as in (A), using KallR
signals to normalize the transfection efﬁciency.
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and K32, are critical for its interaction with nucleo-
phosmin (NPM1) (19), which can regulate APE1’s
endoribonuclease activity (48–50). It is possible that
ubiquitination on these Lys residues affects the interaction
of APE1 with NPM1, and its function for RNA quality
control (48).
The monoubiquitinated form of APE1 was an abundant
form of uAPE1, and in the present study we found that
the uAPE1 was kept inside the nucleus. The nuclear local-
ization of uAPE1 differs from our earlier observation (22),
in which a ubiquitin-APE1 fusion protein was excluded
from nuclei. Obviously, the fusion protein encoded
in the expression vector in the previous study is translated
in cytosol. These studies thus point out that uAPE1
cannot be transported through nuclear membrane. The
present data showed that in situ ubiquitination resulted
in uAPE1 formation in nuclei. Therefore, ubiquitina-
tion may have profound effects on APE1’s DNA repair
and gene regulatory functions, albeit transiently (51). This
concept was supported with the results shown in Figure 6.
The HEK293 T-Rex derivatives provides an experimental
system ideal for our gene array analysis, as the wt-APE1
and ub-APE1 genes could be integrated in an identical
genomic locus and were induced with doxycycline (52).
In this tightly controlled system, there was a clear tendency
that expression of the mu-APE1 enhance the global gene
suppression (Figure 6). Therefore, we propose that
once ubiquitinated, APE1 may increase its existence on
genomic DNA and its role as a gene repressor. DNA
binding assays using ﬂuorescence anisotropy measurement
corroborate this scenario, where ub-APE1 fusion protein
showed persisting DNA afﬁnity in higher range of salt
concentration in the DNA binding assay than the intact
APE1 protein (Supplementary Figure S3). Since puriﬁed
ubiquitin did not bind DNA (Supplementary Figure S3),
the increased afﬁnity for DNA must be due to an altered
biochemical property introduced to APE1 by the ubiqui-
tin conjugation. Given the fact that interaction of APE1
with HDAC1 was enhanced by ubiquitination (Figure 6),
increased afﬁnity for the genomic DNA may enable
APE1 to downregulate a number of genes via HDAC1-
dependent deacetylation of nearby histones. Such a
gene regulatory mechanism likely has a broader inﬂu-
ence than that of those involved with nCaRE-dependent
genes.
Figure 5. Presence of uAPE1 in nuclei. (A) Immunocytochemistry of T233E APE1 in 2DN cells. T233E expressed in 2DN cells without (left) or with
(right) MG132 treatment, and stained with rhodamine (red). (B) Presence of uAPE1 in nuclear fraction. HCT116 (1–4), SW480 (5–8) and A549
(9–12) were transiently transfected with wt (1, 2, 5, 6, 9, 10) or T233E (3, 4, 7, 8, 11, 12) APE1 and treated with MG132. After 24h, cell extracts were
fractionated to cytosolic (1, 3, 5, 7, 9, 11) and nuclear (2, 4, 6, 8, 10, 12) fractions, and analyzed for muAPE1 along with HSP90 and Lap2 as
cytosolic and nuclear marker respectively. (C) Presence of uAPE1 in chromatin assembly. Transiently transfected cells (wtAPE1: 1, 3, 5, 7, 9, 11;
T233E: 2, 4, 6, 8, 10, 12) were cross-linked with formaldehyde to trap proteins associated with chromatin. Cells were then sonicated for 5s to only
break cellular membrane. Insoluble proteins, not associated to genomic DNA, were removed from soluble fraction by centrifugation (1, 2, 5, 6, 9, 10). The
detailed procedure are described in the Supplementary Data. (D) 293/wtAPE1 (left) or 293/muAPE1 (right), both induced by dox for 16h
(Supplementary Figure S2), were treated with formaldehyde in NaCl at 120mM (Lanes 1 and 2), 500mM (3) and 10mM (4), and sonicated for
10s once (1, 3, 4) or for 10 times (2). (Top) Total and (bottom) soluble fraction. (E) Enhancement of interaction of APE1 with HDAC1 by
monoubiquitination. HCT116 cells co-expressing HDAC1-FLAG with wtAPE1 (1 and 2) or ub-APE1 fusion (3 and 4) were immunoprecipitated with
FLAG epitope and analyzed with a-APE1. 1 and 3: total input, 2 and 4: IP fractions. Asterisk (*): truncated APE1.
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provided evidence of the role of ubiquitination in en-
hancing APE1’s gene suppression, we did not categorize
genes according to biological functions such as apoptosis.
However, we found many genes involved in stress re-
sponses were downregulated in the cells expressing ub-
APE1 compared to that of wtAPE1, including ferritin
and TUBA1 which we conﬁrmed in RT–PCR assay
(Supplementary Figure S6B). Interestingly, some genes
that were activated with induction of wtAPE1 were
among what were previously reported as genes suppressed
in APE1-downregulated cells (53) (Supplementary
Figure S6C). It should be noted, however, that the experi-
mental strategies, materials, and methods were very dif-
ferent between the previous and our studies, and so
comparison between these may be difﬁcult.
Although the present results are more focused on the
gene regulatory function of APE1, another interesting
question is how ubiquitination alters APE1’s repair
activity. To know whether mu-APE1 fusion protein can
singly repair AP sites, we used an APE-negative E. coli
mutant and carried out a complementation assay (survival
curve) against methyl methanesulfonate (MMS) that
generates AP sites in the cells (Supplementary Figure
S3F). There was no noticeable difference in the comple-
mentation activity, suggesting that the AP endonuclease
activity of ub-APE1 fusion protein is comparable to that
of the wt-APE1. It should be noted, however, that we
cannot exclude the possibility that ubiquitination may
alter the interaction of APE1 with the other repair
enzymes in mammalian cells. Dedicated future studies
are necessary to answer the question.
To know the inﬂuence of MDM2 on APE1 ubiquiti-
nation, MEFs that speciﬁcally lack the MDM2 genes
was used (Figure 2). Although the present study indicated
that other backup E3 enzymes exist in the cells, we have
several reasons to believe that MDM2 is a functional
E3 ligase and degradation stimulator for APE1. As previ-
ously reported, expression of MDM2 enhanced APE1
ubiquitination (22). Also, using the unique ubiquitination
assay (Figure 2C), MDM2 was able to ubiquitinate APE1,
an activity that was enhanced by the Glu substitution for
APE1’s T233. Finally, in the MDM2
 /  MEF and A549
cells, expression of MDM2 or ubiquitin decreased uAPE1.
It is known that forced expression of the wt-ubiquitin can
lead to degradation of a target protein in certain cases
Figure 6. Effect of muAPE1 on gene regulation. (A) deﬁnition of distance (D) to assess the extent of ‘enhancement’ by muAPE1 (or wtAPE1). Genes
were grouped based on their fold increase/decrease by dox for 16h. In the example, D-value was calculated for a gene that was activated by muAPE1
at highest, then by wtAPE1, and by ctl at least. Idox+ and Idox-: gene expression dosages with or without doxycycline. (B) Histograms of D values.
Left: genes that are activated; Right: genes that are suppressed by wtAPE1 and ub-APE1. (C) Median values of the histograms in (B).
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positive role of MDM2 for degradation of APE1 via
ubiquitination. Based on the present results, we revised
the model of the mechanism of APE1 ubiquitination
(21) in Figure 7. While MDM2 contributes to APE1
ubiquitination and responds to the phosphorylation
event at the T233 position, there must be backup ubiquitin
E3 ligase(s) that react on APE1. The availability of other
E3 ligases likely depends on tissue types and cell cycle.
Once the reaction proceeds beyond the
monoubiquitination stage, MDM2 polyubiquitinates
APE1 for degradation. It is likely that MDM2 may
possess an additional role in facilitating degradation
after APE1 polyubiquitination by a similar mechanism
proposed for p53 degradation (55–57). The balance
between mono- and poly-ubiquitination may be controlled
by other factors such as deubiquitinases which need
focused investigations. Currently we do not know about
the backup E3 ligases for APE1 ubiquitination as there are
more than 600 E3 ligases are identiﬁed in cells, although
CHIP (C-terminus of HSC70-interacting protein) was
recently identiﬁed as an E3 ligase actor for degradation
of DNA polymerase-beta (58). It would be interesting to
test the possibility if CHIP also can ubiquitinate APE1,
especially after phosphorylation of T233. Regardless, it is
possible that T233 phosphorylation need to precede for
yet unidentiﬁed E3 ligase(s) to act on APE1.
Our observation that ubiquitination of endogenous
APE1 was enhanced by the expression of CDK5/p35
underscores the physiological and pathophysiological sig-
niﬁcance of APE1 PTM. While CDK2, CDK4 and CDK6
are essential for normal cell-cycle initiation and check-
point, speciﬁc expression of CDK5 in post-mitotic
neuronal cells suggests its unique function in the brain
(35,59). Interestingly, any abnormal stimuli to initiate
cell growth in neurons invoke activation of CDK5, and
result in apoptotic cell death (36). As in studies with other
cell types, APE1 has been known to be downregulated
before apoptosis, and so it is possible that APE1 phos-
phorylation occurs in the early time point of apoptosis.
Although not systematically analyzed, our preliminary
assays indicated that CDK5 was expressed in the entire
cancer cell lines analyzed (data not shown). Therefore, it is
conceivable that a low level of expression of this protein
phosphorylates APE1, which serves as a trigger for
ubiquitination. It is important to understand precisely
what stimuli activate CDK5 or its cofactors p35/p25 in
the cancer cells. Alternatively, CDK4 and CDK6, the
closest paralog of CDK5, may also participate in APE1
modiﬁcation, but in a cell-cycle dependent manner. These
questions need to be tested to understand the effect of the
APE1 regulation in the cancer biology.
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